Document is current
Any future updates will be listed below
-
Authors
Robert, Caroline https://orcid.org/0000-0002-9493-0238
Marabelle, Aurelien https://orcid.org/0000-0002-5816-3019
Herrscher, Hugo https://orcid.org/0000-0002-5594-6464
Caramella, Caroline https://orcid.org/0000-0003-1517-2510
Rouby, Pascal
Fizazi, Karim
Besse, Benjamin
- License Information
-
More Information
Article History
Accepted: 4 June 2020
First Online: 7 July 2020
Competing interests
: C.R. has acted as a consultant of Amgen, Biothera, BMS, MSD, Novartis, Pierre Fabre, Roche, Sanofi and Ultimovacs. A.M. has acted as a consultant of Bayer, BPI, Daichii Sankyo, EISAI, Faron, Genticel, Imaxio, Molecular partners, Onxeo, Pierre Fabre, Pilar partners, Rigontec, Roche and Sanofi/BioNTech. K.F. has served on the advisory boards of AAA, Amgen, Astellas, AstraZeneca, Bayer, Clovis, Curevac, ESSA, Genentech, Janssen, MSD, Orion and Sanofi. C.C. has acted as a consultant of AstraZeneca, BMS, MSD, and Roche. B.B. has conducted research funded by Abbvie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, Ipsen, Merck, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda and Tiziana Pharm. H.H. and P.R. declare no competing interests.
